KiPS c1
CAMi001-A
General
Cell Line |
|
| hPSCreg name | CAMi001-A |
| Cite as: | CAMi001-A (RRID:CVCL_2Z89) |
| Alternative name(s) |
KiPS c1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 19th August 2019 |
| User feedback | |
Provider |
|
| Generator | University of Cambridge (CAM) |
External Databases |
|
| Cellosaurus | CVCL_2Z89 |
| Wikidata | Q54808436 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes |
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 35-39 |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Contact information / weblink | |
| Alternatives to consent | |
| Alternative consent approval number | |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Details on restriction to research project | |
| How may genetic information associated with the cell line be accessed? | |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Please describe how access is provided: | |
| Contact data, institution, or website: | |
| Name of accrediting authority involved? | |
| Approval number | |
| Name of accrediting authority involved? | |
| Approval number | |
| Please describe: | |
| Further constraints on use | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution |
hIPSC Derivation
General |
|
| Source cell type |
An epidermal cell which synthesizes keratin and undergoes a characteristic change as it moves upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell.; Keratinocytes are reportedly CDw210a-negative, CDw210b-positive, CD281-positive, CD282-positive, CD285-positive, IL22Ra1-positive, Human keratinocytes are reportedly capable of secreting BD-2, BD-3, hCAP-18, CXCL1, CXCL5, CXCL8, elafin, MMP-3, NGAL, PDGF-A, S100A7, S100A8, and S100A9. Transcription factors: STAT3-positive.
Synonyms
|
| Age of donor (at collection) | 35-39 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.